ALKERMES | ALKS - Ebit

Aktienkurs
37.55
Täglich Wechseln
-0.81 -2.11%
Monatlich
11.21%
Jährlich
19.51%
Q2 Prognose
33.96




Ebit Veränderung Datum
AbbVie USD 4.73B 1.08B 2026-03
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Amgen USD 3.83B 130M 2026-03
Biogen USD 514.3M 502.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
J&J USD 6.62B 1.51B 2026-03
Malin Corporation EUR -1.1M 300K 2024-12
Merck USD -1.88B 8.12B 2026-03
Minerva Neurosciences USD -4.37M 1.71M 2024-09
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Otsuka Holdings JPY 118.21B 50.97B 2026-03
Ovoca Bio EUR -1.16M 4.48M 2025-06
Pfizer USD 4.99B 340M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03